4/17/09 update
Although the Nasdaq Biotech Index underperformed the Nasdaq Composite Index for the week, the Contest median did manage to cut its CYTD (Contest Year To Date) loss and it continues to outperform the NBI. At Friday's close the NCI was up 6.46% CYTD (vs. up 5.15% CYTD at its 4/9/09 close), the NBI was down -6.07% CYTD (vs. down -4.77% CYTD at its 4/9/09 close), while the Contest median was down -2.52% CYTD (vs. down -4.00% CYTD at its 4/9/09 close).
Powered by Dendreon dynamite, GEORGIA's portfolio rocketed into the Contest lead with three other portfolios closely bunched in the next three places. The CYTD percentages were: GEORGIA up 33.99%, GENE up 31.37%, PRAVN up 30.07% and RKRW up 29.05%.
At Friday's close, 13 of the 32 Contest portfolios were in the black and 19 of the 32 were beating the NBI.
I've reallocated the proceeds of Gilead's $20 buyout of CVTX, using today's closing prices.
Sorry, but no update next week as I'll be traveling.
Have a wonderful weekend folks!
Below is the Top Ten list on 4/17/09:
4/17/09
Rank Name Profit/Loss
1 GEORGIA 33,988
2 GENE 31,370
3 PRAVN 30,073
4 RKRW 29,054
5 BULBA 18,440
6 ASHLEY 10,728
7 ENZYME 10,337
8 WILDER 9,021
9 TECHNET 8,115
10 SCARAM 6,820
(All corrections, especially adjustments for splits, greatly appreciated.) |
